Covered recipient · General Payments record
CESAR ABUCHAIBE
Allopathic & Osteopathic Physicians Internal Medicine Endocrinology, Diabetes & Metabolism
General Payments · PY2018–2024
$2,591.82
- Reported across 63 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $428.49 | 17 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Novo Nordisk AS | $428.49 | 17 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (17)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Novo Nordisk Inc | $22.56 | 01/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097316679 | CMS |
| Novo Nordisk Inc | $16.61 | 02/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096888498 | CMS |
| Novo Nordisk Inc | $15.73 | 03/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097551325 | CMS |
| Novo Nordisk Inc | $16.58 | 04/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097606983 | CMS |
| Novo Nordisk Inc | $24.79 | 05/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097170545 | CMS |
| Novo Nordisk Inc | $12.68 | 06/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097061248 | CMS |
| Novo Nordisk Inc | $24.98 | 06/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096954353 | CMS |
| Novo Nordisk Inc | $22.00 | 07/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097636211 | CMS |
| Novo Nordisk Inc | $22.68 | 08/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097328585 | CMS |
| Novo Nordisk Inc | $16.89 | 08/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097807719 | CMS |
| Novo Nordisk Inc | $124.39 | 08/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096639464 | CMS |
| Novo Nordisk Inc | $22.59 | 09/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097366864 | CMS |
| Novo Nordisk Inc | $7.89 | 09/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097817098 | CMS |
| Novo Nordisk Inc | $26.07 | 10/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097761132 | CMS |
| Novo Nordisk Inc | $14.98 | 11/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097364667 | CMS |
| Novo Nordisk Inc | $31.63 | 11/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1130818096 | CMS |
| Novo Nordisk Inc | $5.44 | 12/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096636183 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.